NDLI: On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

Please wait, while we are loading the content...

Psychopharmacology : Volume 233, Issue 23-24, December 2016

Psychopharmacology : Volume 233, Issue 21-22, October 2016

Psychopharmacology : Volume 233, Issue 19-20, October 2016

Psychopharmacology : Volume 233, Issue 18, September 2016

Association between major depression and cardiovascular risk: the role of antidepressant medication

Alterations in alpha5* nicotinic acetylcholine receptors result in midbrain- and hippocampus-dependent behavioural and neural impairments

Male-specific effects of lipopolysaccharide on glucocorticoid receptor nuclear translocation in the prefrontal cortex of depressive rats

Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

Effect of combined oral doses of Δ9-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea in rat models

The latent structure of impulsivity: impulsive choice, impulsive action, and impulsive personality traits

A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer’s disease

Improvement of attention with amphetamine in low- and high-performing rats

Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking

Selective attention to emotional cues and emotion recognition in healthy subjects: the role of mineralocorticoid receptor stimulation

Enhancing effect of menthol on nicotine self-administration in rats

Effects of typhoid vaccine on inflammation and sleep in healthy participants: a double-blind, placebo-controlled, crossover study

N-acetylcysteine amide (AD4) reduces cocaine-induced reinstatement

Metabolic shift of the kynurenine pathway impairs alcohol and cocaine seeking and relapse

On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol

Erratum to: The continuous performance test (rCPT) for mice: a novel operant touchscreen test of attentional function

Psychopharmacology : Volume 233, Issue 17, September 2016

Psychopharmacology : Volume 233, Issue 15-16, August 2016

Psychopharmacology : Volume 233, Issue 14, July 2016

Psychopharmacology : Volume 233, Issue 13, July 2016

Psychopharmacology : Volume 233, Issue 12, June 2016

Psychopharmacology : Volume 232

Psychopharmacology : Volume 190

Psychopharmacology : Volume 168

Psychopharmacology : Volume 153

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

Content Provider	Springer Nature Link
Author	Vermeeren, Annemiek Vets, Eva Vuurman, Eric F.P.M. Oers, Anita C.M. Jongen, Stefan Laethem, Tine Heirman, Ingeborg Bautmans, An Palcza, John Li, Xiadong Troyer, Matthew D. Wrishko, Rebecca McCrea, Jacqueline Sun, Hong
Copyright Year	2016
Abstract	Suvorexant is a first-in-class orexin receptor antagonist for treating insomnia. There is a general concern that hypnotics may impair next-morning driving ability.The objective of this study was to evaluate next-morning driving performance in older adults after single and repeated doses of suvorexant.Double-blind, randomized, placebo-controlled, 4-period crossover study in 24 healthy volunteers (10 females), aged 65–80 years. Subjects were treated with suvorexant (15 and 30 mg) for eight consecutive nights, zopiclone 7.5 mg nightly on days 1 and 8, and placebo. Driving performance was assessed on days 2 and 9 (9 h after dosing) using a 1-h standardized highway driving test in normal traffic, measuring standard deviation of lateral position (SDLP). Drug-placebo differences in SDLP >2.4 cm were considered to reflect clinically meaningful driving impairment.Driving performance as measured by SDLP was not impaired following suvorexant. Mean drug–placebo differences in SDLP following suvorexant 15 and 30 mg on day 2 and 9 were 0.6 cm or less. Their 90 % CIs were all below the threshold of 2.4 cm for clinical relevance and included zero, indicating effects were not clinically meaningful or statistically significant. Symmetry analysis showed no significant differences between the number of participants who had SDLP differences >2.4 cm and those who had SDLP differences <−2.4 cm following suvorexant.There was no clinically meaningful residual effect of suvorexant 15 and 30 mg on next-morning driving (9 h after bedtime dosing) in healthy older adults, as assessed by mean changes in SDLP and by the number of participants on drug versus placebo that exceeded a predetermined threshold for clinically meaningful impairment.
Starting Page	3341
Ending Page	3351
Page Count	11
File Format	PDF
ISSN	00333158
Journal	Psychopharmacology
Volume Number	233
Issue Number	18
e-ISSN	14322072
Language	English
Publisher	Springer Berlin Heidelberg
Publisher Date	2016-07-16
Publisher Place	Berlin, Heidelberg
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Hypnotics Suvorexant Zopiclone Orexin antagonist Driving Elderly Neurosciences Pharmacology/Toxicology Psychiatry
Content Type	Text
Resource Type	Article
Subject	Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem

Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.

On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol

The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia

Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

Similar Documents

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers

On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers

On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers

Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem

Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.

On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol

The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia

Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly